Evidence map›Paper›PMID 33557678›Full record

ArticleJournal of child neurology2021

Postmortem Analyses in a Patient With Succinic Semialdehyde Dehydrogenase Deficiency (SSADHD): II. Histological, Lipid, and Gene Expression Outcomes in Regional Brain Tissue.

Dana C Walters, Regan Lawrence, Trevor Kirby, Jared T Ahrendsen, Matthew P Anderson, Jean-Baptiste Roullet, Eric J Murphy, K Michael Gibson, SSADH Deficiency Investigators Consortium (SDIC)

Open access · greenAbstract readCase Reports
In one paragraph

Article in Journal of child neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Central Dysmyelination in SSADH-Deficient Humans and Mice.Annals of clinical and translational neurology · 2025
    Observational
  2. Delays in latencies of median-nerve evoked magnetic fields in patients with succinic semialdehyde dehydrogenase deficiency.Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology · 2024
    Article
  3. Article
  4. Gene therapy for neurotransmitter-related disorders.Journal of inherited metabolic disease · 2024
    Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Dana C WaltersDepartment of Pharmacotherapy, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA, USA.ORCID 0000-0002-4761-7505
Regan LawrenceDepartment of Biomedical Sciences, University of North Dakota School of Medicine and Health Sciences, Grand Forks, ND, USA.
Trevor KirbyDepartment of Pharmacotherapy, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA, USA.
Jared T AhrendsenDepartment of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
Matthew P AndersonDepartment of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
Jean-Baptiste RoulletDepartment of Pharmacotherapy, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA, USA.
Eric J MurphyDepartment of Biomedical Sciences, University of North Dakota School of Medicine and Health Sciences, Grand Forks, ND, USA.
K Michael GibsonDepartment of Pharmacotherapy, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA, USA.ORCID 0000-0003-4465-1318
SSADH Deficiency Investigators Consortium (SDIC)
Washington State University Spokane · USBeth Israel Deaconess Medical Center · USUniversity of North Dakota · US

Funding

Natural History of Succinic Semialdehyde Dehydrogenase Deficiency (SSADHD), a Heritable Disorder of GABA MetabolismR01HD091142 · NICHD · WASHINGTON STATE UNIVERSITY · PI Phillip Lawrence Pearl · 2018 to 2026
$5.3M
2020 International Scientific conference on succinic semialdehyde dehydrogenase deficiency (SSADHD)R13NS116963 · NINDS · WASHINGTON STATE UNIVERSITY · PI ROULLET, JEAN-BAPTISTE O · 2020 to 2020
$20k
NICHD NIH HHS R01 HD091142NINDS NIH HHS R13 NS116963
6 · The paper itself

Abstract

This study has extended previous metabolic measures in postmortem tissues (frontal and parietal lobes, pons, cerebellum, hippocampus, and cerebral cortex) obtained from a 37-year-old male patient with succinic semialdehyde dehydrogenase deficiency (SSADHD) who expired from SUDEP (sudden unexplained death in epilepsy). Histopathologic characterization of fixed cortex and hippocampus revealed mild to moderate astrogliosis, especially in white matter. Analysis of total phospholipid mass in all sections of the patient revealed a 61% increase in cortex and 51% decrease in hippocampus as compared to (n = 2-4) approximately age-matched controls. Examination of mass and molar composition of major phospholipid classes showed decreases in phospholipids enriched in myelin, such as phosphatidylserine, sphingomyelin, and ethanolamine plasmalogen. Evaluation of gene expression (RT

Indexed as

AdultAmino Acid Metabolism, Inborn ErrorsAutopsyBrainDevelopmental DisabilitiesGene ExpressionHumansLipidsMaleSuccinate-Semialdehyde DehydrogenaseLipidsSuccinate-Semialdehyde Dehydrogenasebrain lipidsGABAGABA receptorsgene expression profilesglutamate receptorssuccinic semialdehyde dehydrogenase deficiency

Identifiers

PMID33557678
PMCPMC8349921
OpenAlexW3127908757

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.